Moreover, animal experiments, either by implanting PIK3C2A downregulated tumors or by using PI3K‐C2α specific inhibitors, are warranted to determine whether PI3K‐C2α inhibition can sensitize resistant HNSCC tumors to EGFR inhibition. This evidence concerns the gene PIK3C2A and head and neck squamous cell carcinoma.